InvestorsHub Logo
Followers 59
Posts 11461
Boards Moderated 0
Alias Born 07/16/2006

Re: None

Monday, 11/05/2018 7:04:17 AM

Monday, November 05, 2018 7:04:17 AM

Post# of 20689
Momenta initiated with an Overweight at Piper Jaffray

Piper Jaffray analyst Danielle Brill started Momenta Pharmaceuticals with an Overweight rating and $35 price target. The company offers a "rare" biotech investment opportunity as its stock is "super cheap" and its anti-FcRn therapies could be game changing for treating auto-immune diseases, Brill tells investors in a research note. Momenta's proprietary pipeline has "major blockbuster potential and is underappreciated by investors," says the analyst.

Read more at:
https://thefly.com/landingPageNews.php?id=2817019